Furthermore, clinicopathological data between the BRAF mutant/MSS cancers and BRAF wild type/MSS cancers, also correlated in terms of a more advanced stage of presentation, comparable ages of onset, and equal gender distribution [37]. The gene discussed is BRAF; the disease is cancer.